Literature DB >> 27789145

Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.

Alessandro Manenti1, Sarah M Tete2, Kristin G-I Mohn3, Åsne Jul-Larsen4, Elena Gianchecchi5, Emanuele Montomoli6, Karl A Brokstad7, Rebecca J Cox8.   

Abstract

Two different influenza vaccines are generally used in many countries; trivalent live attenuated influenza vaccine (LAIV3) and trivalent inactivated influenza vaccine (IIV3). Studies comparing the antibody response to IIV3 and LAIV3 commonly investigate the seroprotective response by hemagglutination-inhibition (HI) assay. However, there is limited data regarding comparative analysis of IgG subclass and IgA responses induced by LAIV3 and IIV3. Fifteen children <5years received 2 doses of LAIV3 while 14 children aged 10-17years received one dose. In addition, 15 adults were vaccinated with either intranasal LAIV3 or intramuscular IIV3. We analyzed the H3N2 humoral responses by HI assay and the hemagglutinin (HA) specific IgG1, IgG2, IgG3, IgG4 and IgA1 responses by ELISA. Furthermore, we investigated the avidity of induced IgG antibodies. Pre-existing seroprotective HI antibodies were present in adults (73%) previously vaccinated with IIV3. Vaccination resulted in a significant increase in HI titers in all groups, except LAIV3 vaccinated adults. Furthermore, a negative correlation between age and HI titers in LAIV3 vaccinated subjects was observed post-vaccination. LAIV3 in children and IIV3 in adults induced HA-specific IgG1, low IgG3 but no IgG2 or IgG4. Moreover, significant IgA1 responses were only induced in children. Interestingly, IIV3 and LAIV3 induced IgG antibodies with comparable and significantly augmented avidity post-vaccination in children and adults. Our results suggest that age and/or exposure history play a significant role in determining the antibody response. Clinical trial registry: ClinicalTrials.gov NCT01003288 and NCT01866540. Copyright Â
© 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibody response; IgA; IgG subclass; Influenza; LAIV3; Live attenuated influenza vaccine

Mesh:

Substances:

Year:  2016        PMID: 27789145     DOI: 10.1016/j.vaccine.2016.10.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Reply to Lindsey, Höschler, and de Silva.

Authors:  Laura Matrajt; M Elizabeth Halloran; Rustom Antia
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

Review 2.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

3.  A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.

Authors:  Katherine V Williams; Bo Zhai; John F Alcorn; Mary Patricia Nowalk; Min Z Levine; Sara S Kim; Brendan Flannery; Krissy Moehling Geffel; Amanda Jaber Merranko; Jennifer P Nagg; Mark Collins; Michael Susick; Karen S Clarke; Richard K Zimmerman; Judith M Martin
Journal:  Vaccine       Date:  2021-12-21       Impact factor: 3.641

4.  Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Authors:  Madhusudan Rajendran; Raffael Nachbagauer; Megan E Ermler; Paul Bunduc; Fatima Amanat; Ruvim Izikson; Manon Cox; Peter Palese; Maryna Eichelberger; Florian Krammer
Journal:  mBio       Date:  2017-03-21       Impact factor: 7.867

Review 5.  How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.

Authors:  Elena Gianchecchi; Alessandro Manenti; Otfried Kistner; Claudia Trombetta; Ilaria Manini; Emanuele Montomoli
Journal:  Influenza Other Respir Viruses       Date:  2019-06-21       Impact factor: 4.380

6.  A proteomics-based method for identifying antigens within immune complexes.

Authors:  Stephanie Menikou; Andrew J McArdle; Ming-Shi Li; Myrsini Kaforou; Paul R Langford; Michael Levin
Journal:  PLoS One       Date:  2020-12-23       Impact factor: 3.240

7.  Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.

Authors:  Francesca Dapporto; Serena Marchi; Margherita Leonardi; Pietro Piu; Piero Lovreglio; Nicola Decaro; Nicola Buonvino; Angela Stufano; Eleonora Lorusso; Emilio Bombardieri; Antonella Ruello; Simonetta Viviani; Eleonora Molesti; Claudia Maria Trombetta; Alessandro Manenti; Emanuele Montomoli
Journal:  J Immunol Res       Date:  2022-08-31       Impact factor: 4.493

8.  Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?

Authors:  Laura Matrajt; M Elizabeth Halloran; Rustom Antia
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

9.  Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.

Authors:  Adoración Navarro-Torné; Finnian Hanrahan; Barbara Kerstiëns; Pilar Aguar; Line Matthiessen
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

10.  Convergent antibody evolution and clonotype expansion following influenza virus vaccination.

Authors:  David Forgacs; Rodrigo B Abreu; Giuseppe A Sautto; Greg A Kirchenbaum; Elliott Drabek; Kevin S Williamson; Dongkyoon Kim; Daniel E Emerling; Ted M Ross
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.